The Pancreatic Cancer Collective is an initiative of the Lustgarten Foundation and Stand Up To Cancer to improve pancreatic cancer patient outcomes. The Pancreatic Cancer Collective, will accelerate research for pancreatic cancer patients who desperately need better treatments. Through the Collective, these two leading organizations in the cancer community, with input from thought leaders, will create a dynamic and fluid network to engage and influence medical institutions, researchers and companies, aligned to achieve something bigger and more meaningful, in particular to:
- Inspire collaboration among people who haven’t worked together.
- Spread funding to new centers.
- Leverage Artificial Intelligence (AI) approaches.
- Improve and develop new diagnosis and treatments for pancreatic cancer.
- Utilize the breadth and expertise of existing teams and researchers supported by SU2C and the Lustgarten Foundation to support new investigators coming into the field, building expertise and capacity for additional research.
The Pancreatic Cancer Collective is driven to innovate and accelerate pancreatic cancer research so that all patients become long term survivors.
Since 2012, the Lustgarten Foundation and Stand Up To Cancer have built a robust and illustrious collaboration, jointly funding more than 200 investigators across 31 leading research centers in both the United States and the United Kingdom. These efforts include four of SU2C’s signature Dream Teams as well as five Research Teams, including two Convergence Teams bringing together computational experts with clinical oncologists. Cancer Interception, research supporting the earliest diagnosis of pancreatic cancer even before the cancer may have fully formed, is the focus of one of the Dream Teams and one of the Research Teams. All told, these collaborative teams have planned, started or completed 23 clinical trials. The Pancreatic Cancer Collective will build on this momentum and push the boundaries of what can be accomplished even further.